Space-Time Symmetries: P and CP Violation

We begin with a few remarks on an explicit construction of a Bargmann-Wightman-Wigner-type quantum field theory [Phys. Lett. B {\bf 316}, 102 (1993)] in which bosons and associated antibosons have opposite relative intrinsic parities. We then construct $(1,0)\oplus(0,1)$ Majorana ($CP$ self conjugate) and Majorana-like ($C\Gamma^5$ self conjugate, $\Gamma^5=$ chirality operator) fields. We point out that this new structure in the space time symmetries may be relevant to $P$ and $CP$ violation.Comment: Talk presened by D. V. Ahluwalia at the III International Wigner Symposium, Christ Church, Oxford, September 1993

Legacy data and cosmological constraints from the angular-size/redshift relation for ultra-compact radio sources

We have re-examined an ancient VLBI survey of ultra-comact radio sources at 2.29 GHz, which gave fringe amplitudes for 917 such objects with total flux density >0.5 Jy approximately. A number of cosmological investigations based upon this survey have been published in recent years. We have updated the sample with respect to both redshift and radio information, and now have full data for 613 objects, significantly larger than the number (337) used in earlier investigations. The corresponding angular-size/redshift diagram gives Omega_m=0.25+0.04/-0.03, Omega_\Lambda=0.97+0.09/-0.13 and K=0.22+0.07/-0.10. In combination with supernova data, and a simple-minded approach to CMB data based upon the angular size of the acoustic horizon, our best figures are Omega_m=0.298+0.025/-0.024, Omega_\Lambda=0.702+0.035/-0.036 and K= 0.000+0.021/-0.019. We have examined simple models of dynamical vacuum energy; the first, based upon a scalar potential V(phi)=omega_C^2 phi^2/2, gives w(0)=-1.00+0.06/-0.00, (dw/dz)_0=+0.00/-0.08; in this case conditions at z=0 require particular attention, to preclude behaviour in which phi becomes singular as z -->infinity. For fixed w limits are w=-1.20+0.15/-0.14. The above error bars are 68% confidence limits.Comment: 24 pages, 9 figure

Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology

Cardiovascular diseases (CVD) are the leading cause of mortality both in men and women. In Europe, about 55% of all females' deaths are caused by CVD, especially coronary heart disease and stroke. Unfortunately, however, the risk of heart disease in women is underestimated because of the perception that women are 'protected' against ischaemic heart disease. What is not fully understood is that women during the fertile age have a lower risk of cardiac events, but this protection fades after menopause thus leaving women with untreated risk factors vulnerable to develop myocardial infarction, heart failure, and sudden cardiac death. Furthermore, clinical manifestations of ischaemic heart disease in women may be different from those commonly observed in males and this factor may account for under-recognition of the disease. The European Society of Cardiology has recently initiated an extensive 'Women at heart' program to coordinate research and educational initiatives on CVD in women. A Policy Conference on CVD in Women was one of the first steps in the development of this program. The objective of the conference was to collect the opinion of experts in the field coming from the European Society of Cardiology member countries to: (1) summarize the state-of-the-art from an European perspective; (2) to identify the scientific gaps on CVD in women; and (3) to delineate the strategies for changing the misperception of CVD in women, improving risk stratification, diagnosis, and therapy from a gender perspective and increasing women representation in clinical trials. The Policy Conference has provided the opportunity to review and comment on the current status of knowledge on CVD in women and to prioritize the actions needed to advance this area of knowledge in cardiology. In the preparation of this document we intend to provide the medical community and the stakeholders of this field with an overview of the more critical aspects that have emerged during the discussion. We also propose some immediate actions that should be undertaken with the hope that synergic activities will be implemented at European level with the support of national health care authorities

Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study

PURPOSE: To assess the diagnostic efficacy, safety and tolerability of mangafodipir trisodium (MnDPDP, Teslascan) in MR imaging of the liver. MATERIAL AND METHODS: Eighty-two patients from 4 centres underwent MR imaging with pre-contrast sequences including T1-weighted SE and GRE, and T2-weighted turbo SE sequences. MnDPDP at a dose of 5 mumol/kg b.w. was administered by slow i.v. infusion, and 20-60 min after infusion the T1-weighted SE and GRE sequences were repeated. Diagnostic efficacy was evaluated by counting the number of lesions and by evaluating whether more information for lesion characterisation was available in post-contrast images. Safety and tolerability were assessed by recording adverse events and infusion-related discomfort. RESULTS: Significantly more lesions were found in MnDPDP-enhanced T1-weighted SE and GRE images than in unenhanced images of the same sequences. More lesions were also found in these images compared with T2-weighted images at a level of marginal significance. More information was obtained from MnDPDP-enhanced images in 40 cases. Mild to moderate adverse events were experienced by 17% of the patients. CONCLUSION: MnDPDP-enhanced images can improve lesion detection in the liver and are helpful for lesion characterisation. To obtain optimal diagnostic information of liver lesions T2-weighted images are also valuable. MnDPDP is a safe contrast agent for MR imaging of liver lesions